4-Antibody

4-Antibody closes CHF 6 million series A financing, appoints Sijmen de Vries as CEO

Published in Pharma Investments, Ventures and Law Weekly, September 24th, 2006

4-Antibody, a Basel-based biotechnology company focused on exploiting its platform to develop de novo and improved fully human antibodies, announced the closing of a CHF 6 million Series A financing and the appointment of Sijmen de Vries, MD, MBA, as its new CEO.

The Series A financing was provided by a consortium of existing investors including Biomedinvest AG (CH), Grazia Equity (D), Life Science Partners (NL) and Mulligan Biocapital (D). Proceeds will be used to develop internal pipeline projects initially to pre- clinical proof of concept and establish licensing partnerships with biotech and pharma partners.

Sijmen joins 4-Antibody from...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly

Source: Pharma Investments, Ventures and Law Weekly (2006-09-24)

More Articles from Pharma Investments, Ventures and Law Weekly

Ablynx
Ablynx completes EUR 40 million series C financing
Adams Respiratory Therapeutics
Adams Respiratory Therapeutics reports 35% increase in net sales
Affymetrix
Affymetrix announces update regarding stock option grants
Arrowhead Research
Arrowhead names Paul McDonnel as VP, finance and accounting
Arrowhead Research
Arrowhead raises additional capital from institutional shareholders
BaroFold
BaroFold appoints a new chief business officer
More from this issue of Pharma Investments, Ventures and Law Weekly

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry